Zynerba falls on Phase II cannabidiol miss

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) fell $8.39 (56%) to $6.67 on Monday after reporting that its synthetic cannabidiol (CBD) gel ZYN002 missed the primary endpoint in the Phase II STAR 1 trial to treat focal seizures in adult epilepsy patients. The company said it will continue the open-label STAR 2 trial of ZYN002 to determine next steps for the candidate in the indication.

In the double-blind STAR 1 trial, low- and high-dose ZYN002 failed to significantly improve the median percent reduction in focal seizure frequency from baseline to week 12 vs. placebo (18.4% and 14%, respectively, vs. 8.7%). The company said ZYN002 also missed all secondary endpoints vs. placebo. ZYN002 was well tolerated with no treatment-related serious adverse events reported...